NETTER-1 phase III: Progression-free survival, radiographic response, and preliminary overall survival results in patients with midgut neuroendocrine tumors treated with 177-Lu-Dotatate. Strosberg, J. R., Wolin, E. M., Chasen, B., Kulke, M. H., Bushnell, D. L., Caplin, M. E., Baum, R. P., Kunz, P. L., Hobday, T. J., Hendifar, A., Oberg, K. E., Sierra, M., Kwekkeboom, D. J., Ruszniewski, P. B., Krenning, E. AMER SOC CLINICAL ONCOLOGY. 2016

View details for DOI 10.1200/jco.2016.34.4_suppl.194

View details for Web of Science ID 000378109600188